| Identification | Back Directory | [Name]
Benzamide, N-(cyanomethyl)-4-[5-fluoro-2-[[4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]- | [CAS]
1654776-91-6 | [Synonyms]
JAK-IN-20
Benzamide, N-(cyanomethyl)-4-[5-fluoro-2-[[4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]- | [Molecular Formula]
C28H30FN7O2 | [MOL File]
1654776-91-6.mol | [Molecular Weight]
515.58 |
| Hazard Information | Back Directory | [Uses]
JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC50s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo[1]. | [in vivo]
JAK-IN-20 (compound 32) (3 mg/kg for p.o.; 1 mg/kg for i.v.) shows excellent pharmacokinetics in rats[1].
JAK-IN-20 (10 mg/kg; p.o.; once a day for 3 days) shows anti-inflammatory effect[1].
Pharmacokinetic Parameters of JAK-IN-20 in female Sprague Dawley rats[1].
| parameter | 32 | | PO Dose (mg/kg) | 3 | | Tmax (h) | 0.63(0.25-6) | | Cmax (μg/mL) | 7.82±3.68 | | AUC0-t (μg.h/mL) | 80.18±35.44 | | T1/2,po (h) | 4.77±1.84 | | MRT (h) | 7.54±2.52 | | IV Dose (mg/kg) | 1 | | C0 (μg/mL) | 4.70±2.50 | | AUC0-t (μg.h/mL) | 18.89±1.76 | | Vss (L/kg) | 0.32±0.14 | | CL (mL/min/kg) | 0.85±0.13 | | T1/2,iv (h) | 5.16±3.83 | | MRT (h) | 6.69±4.03 | | %F | 100 |
Wistar rats; 3 mg/kg; p.o. (1% Tween 80 + 99% (0.5%) methyl cellulose in water); 1 mg/kg; i.v. (5% NMP + 5% solutol + 90% normal saline) [1]| Animal Model: | 7-10 weeks, 250-300g, male wistar rats[1] | | Dosage: | | | Administration: | 3 mg/kg for p.o.; 1 mg/kg for i.v. | | Result: | Showed fast oral absorption, higher plasma exposure, extended oral half-life and excellent oral bioavailability of 100%. |
| Animal Model: | Female Sprague Dawley rats ( PGPS rat model)[1] | | Dosage: | 10 mg/kg | | Administration: | P.o.; once a day; 3 days | | Result: | Showed anti-inflammatory effect. |
| [IC 50]
JAK1: 7 nM (IC50); JAK2: 5 nM (IC50); JAK3: 14 nM (IC50) | [References]
[1] Desai J, et al. Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor. Bioorg Med Chem Lett. 2022; 66:128728. DOI:10.1016/j.bmcl.2022.128728 |
|
|